IP Library › Patent Application 12223043
Patent Application
App. No. 12/223,043

Jak2 Tyrosine Kinase Inhibition

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/223,043
Abstract

The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.

Claims (17)

1 . A method for treating myeloproliferative disorders in a patient comprising administering to the patient a therapeutically effective amount of:

or a pharmaceutically acceptable salt thereof.

2 . The method according to claim 1 wherein the myeloproliferative disorder is polycythemia vera.

3 . The method according to claim 1 wherein the myeloproliferative disorder is essential thrombocythemia.

4 . The method according to claim 1 wherein the myeloproliferative disorder is myeloid metaplasia with myelofibrosis.

5 . The method according to claim 1 wherein the myeloproliferative disorder is chronic myelogenous leukemia.

6 . The method according to claim 1 wherein the myeloproliferative disorder is chronic myelomonocytic leukemia.

7 . The method according to claim 1 wherein the myeloproliferative disorder is hypereosinophilic syndrome.

8 . The method according to claim 1 wherein the myeloproliferative disorder is juvenile myelomonocytic leukemia.

9 . The method according to claim 1 wherein the myeloproliferative disorder is systemic mast cell disease.

10 . The method according to claim 1 wherein the myeloproliferative disorder is idiopathic myelofibrosis.

11 . The method according to claim 1 wherein the myeloproliferative disorder is systemic mastocytosis.

12 . The method according to claim 1 wherein the myeloproliferative disorder is chronic neutrophilic leukaemia.

13 . The method according to claim 1 wherein the myeloproliferative disorder is unclassified MPD.

14 . The method according to claim 1 wherein the myeloproliferative disorder is myelodysplastic syndrome.

15 . A method for inhibiting JAK2 tyrosine kinase, comprising contacting:

or a pharmaceutically acceptable salt thereof, and the JAK2 tyrosine kinase.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2011
From: MERCK SHARP & DOHME CORP.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 025719/0236 →
CHANGE OF NAME Recorded Jan 26, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023845/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2009
From: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
To: MERCK & CO., INC.
Reel/Frame 023183/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2009
From: GILES, FRANCIS J.
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 022665/0088 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2009
From: POLLARD, JOHN R.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 022665/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2009
From: GIBBS, JACKSON B.; BUSER-DOEPNER, CAROLYN A.; FREEDMAN, STEVEN J.; MARSHALL, CHRISTOPHER G.
To: MERCK & CO., INC.
Reel/Frame 022665/0357 →